ImmuOne

Based in the United Kingdom, ImmuOne is a startup founded in 2013. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

ImmuOne specializes in providing in vitro cell culture models and services for inhalation safety testing, particularly focusing on human alveolar macrophage responses and epithelial cell cultures. The company offers innovative respiratory tissue models that mimic lung physiology to help companies assess the safety of drugs, chemicals, and consumer products without relying on animal testing.